# Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

> **NCT00759083** · PHASE4 · WITHDRAWN · sponsor: **The Medicines Company**

## Conditions studied

- Heparin-Induced Thrombocytopenia
- Heparin-induced Thrombocytopenia and Thrombosis Syndrome

## Interventions

- **DRUG:** bivalirudin

## Key facts

- **NCT ID:** NCT00759083
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-09
- **Primary completion:** 2009-09
- **Final completion:** 2010-05-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was discontinued early due to inadequate patient enrollment. No patients were enrolled.
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759083, "Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00759083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*